Germline mutations in the DNA repair system genes in prostate cancer patients
https://doi.org/10.1234/XXXX-XXXX-2016-7-21-23
Abstract
Timeliness. Prostate cancer (PC) is clinically and genetically heterogeneous disorder characterized by high prevalence and mortality. The aim. Germline mutations analysis in PC patients. Methods. DNA samples from blood and normal prostate tissues from 8 PC patients. Analysis of mutations was carried using whole exome sequencing. Results. In PC patients a number of pathogenic mutations in DNA repair system genes was found. Conclusions. The data supply information on molecular characterization of PC and contribute to the genetic counseling and treatment strategies of PC.
About the Authors
I. R. Gilyazova
Institute of Biochemistry and Genetics, Ufa Science Centre, RAS; Bashkir State University
Russian Federation
Russian Federation
G. B. Kunsbaeva
Bashkir State University
Russian Federation
Russian Federation
M. A. Yankina
Institute of Biochemistry and Genetics, Ufa Science Centre, RAS
Russian Federation
Russian Federation
A. T. Mustafin
Bashkir State Medical University
Russian Federation
Russian Federation
R. I. Safiullin
Bashkir State Medical University
Russian Federation
Russian Federation
V. N. Pavlov
Bashkir State Medical University
Russian Federation
Russian Federation
E. K. Khusnutdinova
Institute of Biochemistry and Genetics, Ufa Science Centre, RAS; Bashkir State University
Russian Federation
Russian Federation
References
1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Barbieri CE, Baca SC, Lawrence MS et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet.2012;44:685-689.
3. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell.2015;163:1011-1025.
4. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics.2009;25(14):1754-1760.
5. DePristo MA, Banks E, Poplin R et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics.2011;43(5):491-498.
6. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nature protocols.2015;10(10):1556-1566.
7. Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31: 1748-1757.
8. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer.2016;16:35-42.
9. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med.2015; 373:1697-708.
10. Isakoff SJ, Mayer EL, He L et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triplenegative breast cancer. J Clin Oncol.2015;33:1902-9.
Review
For citations:
Gilyazova I.R., Kunsbaeva G.B., Yankina M.A., Mustafin A.T., Safiullin R.I., Pavlov V.N., Khusnutdinova E.K. Germline mutations in the DNA repair system genes in prostate cancer patients. Medical Genetics. 2016;15(7):21-23. (In Russ.) https://doi.org/10.1234/XXXX-XXXX-2016-7-21-23
Views:
829
Email this article 